These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22810221)

  • 1. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.
    Clémenson C; Jouannot E; Merino-Trigo A; Rubin-Carrez C; Deutsch E
    Invest New Drugs; 2013 Apr; 31(2):273-84. PubMed ID: 22810221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice.
    Wang Y; Dong L; Bi Q; Li X; Wu D; Ge X; Zhang X; Fu J; Zhang C; Wang C; Li S
    Target Oncol; 2010 Dec; 5(4):237-43. PubMed ID: 21086056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.
    Skvortsova I; Skvortsov S; Raju U; Stasyk T; Riesterer O; Schottdorf EM; Popper BA; Schiestl B; Eichberger P; Debbage P; Neher A; Bonn GK; Huber LA; Milas L; Lukas P
    Radiother Oncol; 2010 Jul; 96(1):108-15. PubMed ID: 20451273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
    Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
    Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer.
    Vesci L; Milazzo FM; Anastasi AM; Petronzelli F; Chiapparino C; Carollo V; Roscilli G; Marra E; Luberto L; Aurisicchio L; Pacello ML; Spagnoli LG; De Santis R
    Oncotarget; 2016 Jan; 7(1):914-28. PubMed ID: 26575422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.
    Ekshyyan O; Rong Y; Rong X; Pattani KM; Abreo F; Caldito G; Chang JK; Ampil F; Glass J; Nathan CO
    Mol Cancer Ther; 2009 Aug; 8(8):2255-65. PubMed ID: 19625495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
    Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
    Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
    Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
    Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
    Adkins D; Ley J; Trinkaus K; Thorstad W; Lewis J; Wildes T; Siegel BA; Dehdashti F; Gay H; Mehan P; Nussenbaum B
    Cancer; 2013 Feb; 119(4):766-73. PubMed ID: 22991252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.
    Zhang N; Erjala K; Kulmala J; Qiu X; Sundvall M; Elenius K; Grénman R
    Radiother Oncol; 2009 Sep; 92(3):388-92. PubMed ID: 19447510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.
    Bozec A; Ebran N; Radosevic-Robin N; Chamorey E; Yahia HB; Marcie S; Gautier M; Penault-Llorca F; Milano G
    Head Neck; 2017 Jan; 39(1):151-159. PubMed ID: 27507562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.
    McNally LR; Rosenthal EL; Zhang W; Buchsbaum DJ
    Cancer Gene Ther; 2009 Mar; 16(3):246-55. PubMed ID: 18846112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
    Bozec A; Sudaka A; Etienne-Grimaldi MC; Brunstein MC; Fischel JL; Milano G
    Oral Oncol; 2011 Oct; 47(10):940-5. PubMed ID: 21862388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
    Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
    Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.
    Brake R; Starnes C; Lu J; Chen D; Yang S; Radinsky R; Borges L
    Mol Cancer Res; 2008 Aug; 6(8):1337-46. PubMed ID: 18708365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optical imaging predicts tumor response to anti-EGFR therapy.
    Helman EE; Newman JR; Dean NR; Zhang W; Zinn KR; Rosenthal EL
    Cancer Biol Ther; 2010 Jul; 10(2):166-71. PubMed ID: 20505368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.